Free Trial

Raymond James Financial's Rating of Oncolytics Biotech on 11/14/2024

On November 14, 2024, Raymond James Financial updated its outlook on Oncolytics Biotech (NASDAQ:ONCY) with the action "Upgrade", setting a "Moderate Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.